; News - Inolife Sciences

Inolife Nominates Dr. Richard Gallo to its Advisory Board

 

Inolife Has Contracted LOK North America to Spearhead Its ISO 13485 Quality Management System Certification and Initiate Its Health Canada Medical Device Licensing

Inolife takes further steps to meet the needs of the medical community through extended partnership, training, and systematization

Inolife R&D Inc. (“Inolife”), announces it has partnered with LOK North America to lead its ISO 13485 Quality Management System review and implementation and initiate its Health Canada Medical Device Licensing. Through this partnership, Inolife will continue to maintain the highest standards of quality control while meeting Health Canada licensing requirements in continued efforts to positively impact the world through the various markets its research and development technologies are serving.The proposed partnership will target a number of areas of Inolife’s business, mainly through documentation and systematization of internal processes and quality management systems, in order to better prepare Inolife for external audits and help in obtaining ISO 13485: 1026 (MDSAP) accreditation.

“We are thrilled to partner with LOK North America, a leader in providing quality systems implementation, management and regulatory solutions for Health Canada licensing,” states Michael Wright, President & Chief Executive Officer of Inolife. “This partnership is another expression of the many ways we are continuing to grow our organization, meet the needs of the medical community and continue our mandate to help as many people as we can with our research, innovation, and devices.”

“LOK North America was created with the firm belief that the whole is greater than the sum of its parts and that the combined expertise of seasoned professionals forms a brain trust essential to the creation of value”, said Louis-Paul Marin, president of LOK North America. “We are excited and proud to offer our quality-assurance and regulatory compliance expertise in the medical device industry to Inolife and help such a high-class organization in its goal to reach new heights.”

About Inolife R&D Inc. / Inolife Sciences Corporation
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. Inolife commercializes patented and FDA-cleared needle-free injection devices. The company was founded to take advantage of novel techniques of the liquid jet and ballistics-based epidermal drug injection that improve patients’ quality of life by making medicines easier to administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.For more information about Inolife and its products please visit www.inolifesciences.com.

Contact:
Michael Wright
President & CEO, Inolife R&D Inc.
Phone: 1 (866) 834-3777
Email: mwright@inolifesciences.com

About LOK North America Inc.

LOK North America is located in Metropolitan Montreal, at the heart of the life science and medical technology environment. They provide targeted assistance to domestic and international clients to help them comply with medical device and IVD regulatory, quality-assurance and clinical requirements worldwide. LOK supports them in the development, testing and governmental approval processes, compliance quality assurance systems, post-marketing compliance, market access and partnering with high quality distributors.LOK is also proud to have a unique offering and provides multiple options/solutions to manufacturers entering the Canadian market.

Contact:
Louis-Paul Marin
President, LOK North America
Phone: 1 (450) 781 1578
Email: marin.lp@lok-corporation.com

 

Inolife Signs LOI With ADW Diabetes to Make Its Inojex Needle-Free Injector Available to Diabetics in USA

Inolife is entering into a Definitive Agreement With ADW Diabetes to Serve Diabetics in USA with FDA Approved Needle-Free Insulin Injectors.

Needle-Free Insulin Injector​Inolife R&D Inc. (“Inolife”), announces it has entered into a Letter of Intent (“LOI”) with ADW Diabetes LLC. (“ADW”) for the distribution of its Inojex® product to people suffering from Diabetes in the United States. The opportunity to work with ADW operates as a way for Inolife to reiterate its commitment to positively impact the world through the various markets its Needle-Free technologies are serving. ADW has a long history of serving hundreds of thousands of Diabetics with innovative solutions aimed at the treatment and management of Diabetes.

Growing from 108 million people in 1980 to 422 million in 2014, Diabetes is one of the leading causes of death, and directly affects people’s quality of life, in many ways. Diabetes is a global issue. In 2015 over 30 million Americans had diabetes and according to the American Diabetes Association, another 84 million adults aged 18 and older had prediabetes. Inolife and ADW will work together to improve the management of this demanding disease.

Michael Wright, President & Chief Executive Officer of Inolife, says, “We are very excited to work with ADW in providing Diabetics with access to our proven and FDA approved Needle-Free Insulin Injection Technology. By connecting innovative Needle-Free Insulin Delivery technologies to ADW’s Diabetic community, we will create new opportunities and synergies that otherwise would not have been available to our companies. Partnering with ADW fits perfectly into our vision that every individual should have the opportunity to receive healthcare that is empowering, safe and respectful.”.

Michael Maguire, President & Chief Executive Officer of ADW states, “We are thrilled to see where the future of Diabetes Management is heading. With Inolife leading the way with their Needle-Free Injectors for people that require Insulin Therapy, the real possibility for people with diabetes now exists to be able to manage their Insulin regimen with more comfort and less stress. The fear of needles is real and is a leading cause for people with Diabetes to not stay on track with their Diabetes care team’s recommendations for optimum blood glucose management. Inolife solves that problem. ADW is excited to team up with Inolife so we can deliver comfort and ease to anyone with Diabetes that has a fear of needles or is looking for an easier way to inject their Insulin.”.With ADW as a new partner for the distribution of Inojex® in the United States, Inolife will have a strategic access to one of the biggest Insulin markets in the world. The collaboration will allow Inolife and ADW to fulfill their common objective of improving the quality of life of people living with the burden of Diabetes.

About Inolife R&D Inc.
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. Inolife commercializes patented and FDA-cleared needle-free injection devices. The company was founded to take advantage of novel techniques of liquid jet and ballistics-based epidermal drug injection that improve patients’ quality of life by making medicines easier to administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.For more information about Inolife and its products please visit www.inolifesciences.com.

Contact:
Michael Wright
President & CEO, Inolife R&D Inc.
Phone: +1 (866) 834-3777
Email: mwright@inolifesciences.com

About ADW Diabetes LLC
ADW Diabetes is a mail order company dedicated to keeping diabetes management affordable. In business for more than 10 years, ADW services hundreds of thousands of people with diabetes annually by providing one of the largest selections of diabetes management items including insulin pump supplies and glucose testing products. With a focus on offering quality brand name products at affordable prices, ADW has grown its business through customer loyalty and their word of mouth reputation as a national leader in the category of diabetes supplies. ADW is involved in and supports the diabetes community and organizations that further diabetes education and research.

To learn more about ADW Diabetes visit www.adwdiabetes.com.

Contact:
Mike Maguire
President & CEO, ADW Diabetes LLC.
Phone: +1 (877) 241-9002
Email: mmaguire@adwdiabetes.com

 

Inolife Announces the Commencement of Its Public Listing Process to Meet Growing Demand for Its Needle-Free Injection Technologies.

Inolife R&D (“Inolife”), is pleased to announce today it aims for the Public Listing of its stocks on the Canadian Securities Exchange (CSE): currently private, the company commenced the listing process for trade on the CSE, by way of a Reverse Takeover (RTO) as a catalyst for accessing the capital needed to support its growth plan.

To that end, following the completion of its RTO all filings were made with a view to obtaining the timely listing of its stocks on the CSE. The application is subject to review and approval by the CSE, a Canadian trading platform aimed at venture market companies. The management team is confident that the application process will go smoothly and expects to be listed in Q2 2018.

Michael Wright, President and Chief Executive Officer of Inolife comments, “This listing will provide access to additional capital to support Inolife’s growth plan and propel the Company into an exciting and rapidly growing industry”. “The ready-to-market products and the next generation needle-free injection technologies of Inolife will shape the Company into an industry leader”, further added Mr. Wright.

 

Inolife signs Letter Of Intent with Namaste to research the use of needle-free injection technologies with medical cannabis

– Inolife R&D Inc. (“Inolife”), is pleased to announce today it has signed a letter of intent with Namaste Technologies Inc. (“Namaste”) for trials in the use of Inolife’s needle-free technologies for the dosing and administration of medical cannabis.

According to the terms of the letter of intent, Namaste will initiate the research and upon the signing of a definitive agreement, Namaste will retain the exclusive rights for the use of Inolife’s needle-free technologies for the cannabis industry. Inolife’s needle-free technologies offer efficient and precise dosing and administration of subcutaneous, intramuscular as well as intradermal medication. Specific dosing is one of the main impediment to adoption of medical   cannabis in various therapeutic fields such as Chronic Pain, Epilepsy, Diabetes, Parkinson, Alzheimer’s and Multiple Sclerosis to name a few.

The terms of the LOI also outline the investment by Namaste into Inolife’s anticipated private placement as well as its go public financing. Inolife R&D Inc. has entered into a reverse merger agreement with 4Touchdowns Capital Inc., and intends to list its common shares on the Canadian Securities Exchange and change its name to Inolife Sciences.

Management Commentary

Sean Dollinger, President and Chief Executive Officer of Namaste comments, “We are very pleased to announce this LOI and proposed partnership our intention to provide research and development of this innovative technology for applications with medical cannabis. We believe that Inolife’s technology could provide the most efficient and accurate method for dosing with medical cannabis. We see a massive opportunity to revolutionize the industry by bringing this exciting technology to the medical cannabis market. We’re delighted to see that industry leading companies like Inolife are recognizing Namaste for its value in its database, platform and brand.”

Michael Wright, President and Chief Executive Officer of Inolife comments, “We’re very excited about the proposed partnership with Namaste. We feel that Namaste is best positioned to deliver on our strategic plan to become an innovator of delivery systems for the medical cannabis industry. We’re pleased to be the first company, in partnership with Namaste, to explore needle-free device technology in the context of medical cannabis delivery. Our needle-free technologies coupled with our intellectual properties and proprietary processes is a perfect fit for medical cannabis. We look forward to working with such a visionary company and contributing to shaping the future of the medical cannabis landscape.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in ecommerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Contact information

Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

About Inolife R&D Inc. / Inolife Sciences Corporation
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing self-administered medical products using novel drug delivery technologies.  The company was founded to take advantage of novel techniques of liquid jet and ballistics- based epidermal drug injection that we believe will improve a patient’s quality of life by making medicines easier to self-administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.

For more information about Inolife and its products please visit www.inolifesciences.com.

Michael Wright
President & CEO
Direct: +1 (866) 834-3777
Email: mwright@inolifesciences.com